April 25, 2017 3:01 AM ET


Company Overview of Oxford BioTherapeutics Ltd

Company Overview

Oxford BioTherapeutics Ltd, a biotechnology company, develops antibody-drug conjugates to treat cancer. It provides OGAP, a target discovery system that provides a range of validated and novel antigen targets identified from a range of cancer types; and develops antibody-based treatments for acute myeloid leukemia and breast, ovarian, and lung cancers. Oxford BioTherapeutics Ltd was formerly known as Oxford Genome Sciences (UK) Limited and changed its name to Oxford BioTherapeutics Ltd in December 2008. The company was incorporated in 2003 and is based in Oxon, United Kingdom with a location in San Jose, California.

94A Innovation Drive

Milton Park


Oxon,  OX14 4RZ

United Kingdom

Founded in 2003


44 1235 861 770


44 1235 861 771

Key Executives for Oxford BioTherapeutics Ltd

Founder, Chief Executive Officer and Director
Senior Director of Finance
UK Site Head and Scientific Director
Senior Vice President of Protein Sciences
Senior Vice President of Non-Clinical Development
Compensation as of Fiscal Year 2016.

Oxford BioTherapeutics Ltd Key Developments

Oxford BioTherapeutics Appoints Bernd Seizinger as Chairman and Jean-Pierre Bizzari as Non-Executive Director

Oxford BioTherapeutics announced a significant strengthening of its oncology focused Board of Directors with the appointment of Bernd Seizinger M.D., Ph.D. as Chairman and Jean-Pierre Bizzari, M.D. as a non-executive director, joining Glenn Begley, Shawn Tomasello, Tom Bradley and Christian Rohlff. Bernd Seizinger brings over 20 years of industry experience, from a number of senior executive board positions in pharma and biotech companies on both sides of the Atlantic. These include Bristol-Myers Squibb (VP oncology drug discovery and VP Corporate and Academic alliances), GPC Biotech (CEO and President), and Chairman of Aprea, Opsona and CryptoMedix. Jean-Pierre Bizzari brings 32 years' experience including as EVP and Group Head of Clinical Oncology at Celgene until 2015, and Sanofi Aventis prior to that, and has directed the clinical development and approval of a number of important anti-cancer medicines.

Oxford BioTherapeutics Limited Presents at Biotech and Money Inv€$tival Showcase, Nov-18-2016 12:30 PM

Oxford BioTherapeutics Limited Presents at Biotech and Money Inv€$tival Showcase, Nov-18-2016 12:30 PM. Venue: The Waldorf Hilton Hotel, Aldwych, London, WC2 4DD, United Kingdom.

Oxford BioTherapeutics Limited Presents at BIO Europe 2016 Conference, Nov-08-2016 11:30 AM

Oxford BioTherapeutics Limited Presents at BIO Europe 2016 Conference, Nov-08-2016 11:30 AM. Venue: KoelnMesse - Congress Center North, Cologne, Germany.

Similar Private Companies By Industry

Company Name Region
Abcellute Ltd. Europe
Abcodia Ltd. Europe
Abeterno Ltd. Europe
Abgentis Limited Europe
Achilles Therapeutics Ltd. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Oxford BioTherapeutics Ltd, please visit www.oxfordbiotherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.